The experimental substantiation of the shelf-life of “Candidocyde” vaccine
DOI:
https://doi.org/10.24959/nphj.17.2148Keywords:
vaccine, antigen, candidiasis, shelf-life, antibody titersAbstract
Because of the difficult situation with the diagnosis and therapy of candidiasis many researchers propose to use vaccines as an alternative to anti-fungal drugs for preventing and treating candidal infections. The authors have developed “Candidocyde” vaccine against candidiasis.
Aim. To determine experimentally the shelf-life of the solution of “Candidocyde” vaccine.
Materials and methods. “Candidocyde” vaccine was stored at two temperature regimes: in the refrigerator at the temperature of 2-8 °C and at the room temperature of (15-25 °C). Antibody titers of the solution of “Candidocyde” vaccine were assessed every three months to prevent and treat candidiasis. For this purpose the reagent kit for immunoassay detection of antibodies of class G to C. albicans using the test system ELISA “Vector-best” was applied.
Results and discussion. When conducting the studies of the vaccine stored in glass vials protected from light at the temperature from 2 ºC to 8 ºC it was found that the activity of the solution was preserved for 2 years and 3 months when preventing and treating candidal infections. The titers of antibodies in animals remained at the level of 1 : 600-1 : 4000 when preventing and treating candidiasis. The positive results were recorded in all animals in the group, i.e. all animals were healthy. It indicates that the solution of “Candidocyde” vaccine is stable for 2 years.
Conclusions. When studying the shelf-life of the solution of “Candidocyde” vaccine based on antigens of cells of C. albicans and C. tropicalis fungi it has been found that it is stable for 2 years of storage in glass vials protected from light at the temperature of 2-8 ºC.
References
Kullberg, B. J. Invasive Candidiasis / B. J. Kullberg, M. C. Arendrup // N. Engl. J. Med. – 2015. – Vol. 373. – P. 1445–1456.
Candidemia and invasive candidiasis in adults: A narrative review / S. Antinori, L. Milazzo, S. Sollima et al. // NCBI. – 2016. – Vol 34. – P. 21–28. doi: 10.1016/j.ejim.2016.06.029
Clinical Practice Guideline for the Management of Candidiasis: 2016 Update by the Infectious Diseases Society of America / P. G. Pappas, C. A. Kauffman, D. R. Andes et al. // Clin. Infect. Dis. – 2016. – Vol. 62, Issue 4. – P. e1–e50. doi: 10.1093/cid/civ933
Cassone, A. Development of vaccines for Candida albicans: fighting a skilled transformer / A. Cassone // Nature Rev. Microbiol. – 2013. – Vol. 11, Issue 12. – P. 884–891. doi: 10.1038/nrmicro3156
Vaccines in the treatment of invasive candidiasis / X. Wang, X. Sui, L. Yan et al. // Virulence. – 2015. – Vol. 6, Issue 4. – P. 1–7. doi: 10.4161/21505594.2014.983015
Біотехнологічне обґрунтування режиму культивування грибів роду Candida / М. В. Рибалкін, Н. І. Філімонова, О. П. Стрілець, Л. С. Стрельников // Укр. біофармац. журн. – 2015. – Т. 36, № 1. – С. 74–76.
Рибалкін, М. В. Визначення оптимального методу дезінтеграції клітин грибів Candida albicans та Candida tropicalis / М. В. Рибалкін // Актуальні питання фарм. і мед. науки та практики. – 2014. – Т. 15, № 2. – С. 71–75.
Оцінка фракцій антигенів дезінтеграту клітин грибів C. albicans та C. tropicalis при попередженні кандидамікозів / М. В. Рибалкін, Н. І. Філімонова, О. П. Стрілець, Л. С. Стрельников // Фармац. журн. – 2015. – Т. 17, № 2. – C. 100–104.
Експериментальне обґрунтування консерванту у складі імунобіологічного препарату для попередження та лікування кандидамікозів / М. В. Рибалкін, Н. І. Філімонова, О. П. Стрілець, Л. С. Стрельников // Фармац. часопис. – 2014. – Т. 31, № 3. – С. 45–49.
Обоснование состава и технологии производства раствора «Кандидоцид» / Н. В. Рыбалкин, Н. И. Филимонова, О. П. Стрилец, Л. С. Стрельников // Фармация Казахстана. – 2015. – Т. 165, № 2. – С. 31–34.
Downloads
Published
Issue
Section
License
Copyright (c) 2017 National University of Pharmacy
This work is licensed under a Creative Commons Attribution 4.0 International License.
Authors who publish with this journal agree to the following terms:- Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution License that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal.
- Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.
- Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work (See The Effect of Open Access).
